Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort | Zendy

Jonathan E. Golub | Zendy; Paul Pronyk | Zendy; Lerato Mohapi | Zendy; Nkeko Thsabangu | Zendy; Mosa Moshabela | Zendy; Helen Struthers | Zendy; Glenda Gray | Zendy; James McIntyre | Zendy; Richard E. Chaisson | Zendy; Neil Martinson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort

Author(s) -

Jonathan E. Golub,

Paul Pronyk,

Lerato Mohapi,

Nkeko Thsabangu,

Mosa Moshabela,

Helen Struthers,

Glenda Gray,

James McIntyre,

Richard E. Chaisson,

Neil Martinson

Publication year - 2009

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e328327964f

Subject(s) - medicine , tuberculosis , isoniazid , human immunodeficiency virus (hiv) , prospective cohort study , cohort , cohort study , sida , virology , aids related opportunistic infections , viral disease , immunology , pediatrics , pathology

The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy. Both IPT and highly active antiretroviral therapy (HAART) used separately result in reductions in tuberculosis risk. There is less information on the combined effect of IPT and HAART. We assessed the effect of IPT, HAART or both IPT and HAART on tuberculosis incidence in HIV-infected adults in South Africa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research